Literature DB >> 2308267

Treatment of polycythemia vera by isovolemic large-volume erythrocytapheresis.

U Kaboth1, K W Rumpf, T Lipp, J Bigge, M Nauck, J H Beyer, W Seyde, W Kaboth.   

Abstract

Excess red blood cells (RBC) in patients with polycythemia vera (PV) are usually removed by repeated phlebotomy. In order to improve the efficacy of this treatment, we used isovolemic large-volume erythrocytapheresis (EA) by a cell separator. A retrospective analysis of our experience with 69 PV patients (206 EA procedures) is reported. EA induced a rapid, well-tolerated, and long-lasting reduction of Hct, Hb, and RBC counts, as well as an immediate disappearance or reduction of clinical symptoms of PV, while tissue oxygen tension - as measured in 8 patients - increased. Hct was reduced by EA from 56.8% +/- 5.6% to 41.9% +/- 6.6%, Hb from 17.5 +/- 2.3 to 12.7 +/- 2.4 g%, RBC counts from 7.4 +/- 0.9 to 5.4 +/- 0.9 x 10(6)/mm3. The mean volume of the apherisate was 1410 +/- 418 ml, (mean Hct 79.7% +/- 9.3%), and the actual RBC volume removed 1113 +/- 367 ml. The isovolemic procedure was well tolerated and the acceptance by patients seemed to be better than with repeated phlebotomy. In 21 patients whose Hct values (Hct before and after EA 58% +/- 5.7% and 41.5% +/- 4.9%) were regularly followed after EA the mean period with Hct less than 50% after a single EA procedure was 6.1 +/- 4.1 months (median, 6); in 14 out of these 21 patients a Hct of less than 43% after EA was reached and their mean period with Hct less than 50% after EA was 7.6 +/- 4.0 months (median, 7.5). For three patients this period was 11, 13, and 15 months, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2308267     DOI: 10.1007/bf01648884

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  18 in total

1.  Complications and causes of death in polycythaemia vera.

Authors:  E CHIEVITZ; T THIEDE
Journal:  Acta Med Scand       Date:  1962-11

2.  [Effectiveness of intensive erythrocytapheresis in polycythemia vera].

Authors:  L G Kovaleva; N N Skachilova; G T Sedova; N N Kalinin; L I Krasiukova
Journal:  Gematol Transfuziol       Date:  1983-10       Impact factor: 0.172

3.  The influence of iron-deficient indices on whole blood viscosity in polycythaemia.

Authors:  D W Milligan; R MacNamee; B E Roberts; J A Davies
Journal:  Br J Haematol       Date:  1982-03       Impact factor: 6.998

4.  Non-hematologic effects of chronic iron deficiency. A study of patients with polycythemia vera treated solely with venesections.

Authors:  W G Rector; N J Fortuin; C L Conley
Journal:  Medicine (Baltimore)       Date:  1982-11       Impact factor: 1.889

5.  Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.

Authors:  P D Berk; J D Goldberg; M N Silverstein; A Weinfeld; P B Donovan; J T Ellis; S A Landaw; J Laszlo; Y Najean; A V Pisciotta; L R Wasserman
Journal:  N Engl J Med       Date:  1981-02-19       Impact factor: 91.245

6.  [Polycythemia vera: clinical aspects and course in 86 patients].

Authors:  F Egli; A Wieczorek; M Niemöller; K Rhyner
Journal:  Schweiz Med Wochenschr       Date:  1988-12-31

7.  Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.

Authors:  P D Berk; J D Goldberg; P B Donovan; S M Fruchtman; N I Berlin; L R Wasserman
Journal:  Semin Hematol       Date:  1986-04       Impact factor: 3.851

8.  Erythrapheresis in patients with polycythaemia secondary to hypoxic lung disease.

Authors:  J A Wedzicha; R M Rudd; M C Apps; F E Cotter; A C Newland; D W Empey
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-12

9.  BLOOD VOLUME IN WOUNDED SOLDIERS : I. BLOOD VOLUME AND RELATED BLOOD CHANGES AFTER HEMORRHAGE.

Authors:  O H Robertson; A V Bock
Journal:  J Exp Med       Date:  1919-01-31       Impact factor: 14.307

10.  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.).

Authors: 
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.